Shuttle Pharma Secures U.S. Patent for Histone Deacetylase Inhibitors

GAITHERSBURG, Md., Sept. 05, 2024 - Shuttle Pharmaceuticals, a company specializing in the discovery and development of drugs aimed at enhancing the outcomes for cancer patients undergoing radiation therapy (RT), has announced the issuance of U.S. Patent No. 12,077,515. The patent, titled "Selective Histone Deacetylase Inhibitors for the Treatment of Human Disease," was officially granted on September 3, 2024. This milestone significantly bolsters Shuttle Pharma’s intellectual property portfolio and supports its continuous efforts to create novel therapeutics that target histone deacetylase (HDAC) enzymes.

The new patent encompasses a range of selective HDAC inhibitors intended to regulate the expression of genes involved in cancer progression, immune responses, and other key biological pathways. These inhibitors are being developed as potential treatments for various human diseases, including cancer. Shuttle Pharma’s main objective is to develop and commercialize unique drugs that enhance the sensitivity of cancers to radiation and protect normal tissues, ultimately aiming to improve the outcomes for cancer patients receiving RT.

Shuttle Pharma employs its proprietary technology to develop innovative cancer immunotherapies. Its product pipeline features selective HDAC inhibitors designed for cancer and immunotherapy applications. The HDAC platform aims to target molecular candidates that may have therapeutic applications beyond cancer, including autoimmune, inflammatory, metabolic, neurological, and infectious diseases.

"We are thrilled to receive this patent, which illustrates our dedication to pioneering therapies that address significant unmet medical needs," stated Anatoly Dritschilo, MD, CEO of Shuttle Pharmaceuticals. "These drug candidates were developed by Shuttle Pharma's scientists based on our strategy to selectively inhibit HDAC6, thereby regulating the innate immune response to irradiated cancer cells. This accomplishment highlights Shuttle Pharmaceuticals' leadership in innovative drug development and positions us for further advancements in our clinical pipeline."

Shuttle Pharma now holds over 20 composition of matter HDAC inhibitor patents across the U.S., Canada, and Europe.

About Shuttle Pharmaceuticals

Shuttle Pharmaceuticals, founded in 2012 by faculty members of the Georgetown University Medical Center, is a specialty pharmaceutical company in the discovery and development stage. The company's focus is on improving the outcomes for cancer patients treated with radiation therapy (RT). Shuttle Pharma's mission is to enhance the lives of cancer patients by developing therapies designed to maximize RT effectiveness while minimizing its side effects. Though RT is a well-established method for treating cancers, Shuttle Pharma aims to increase cancer cure rates, prolong patient survival, and improve the quality of life by developing radiation sensitizers. These sensitizers are intended to be used either as a primary treatment or in conjunction with surgery, chemotherapy, and immunotherapy.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!